Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XeneraTM-1
2017-003131-11Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing xentuzumab + everolimus + exemestane with placebo + everolimus + exemestane (2 arms). Primary endpoint: progression-free survival. Started Aug 2018; status: completed.
02
Drugs
xentuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-003131-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003131-11.